Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer

PURPOSE: Prior clinical trials evaluating cisplatin for non–muscle-invasive bladder cancer (NMIBC) were stopped due to local and systemic toxicity. Currently, there is still a need for improved intravesical therapies, and nanoparticle-based CDDP may be efficacious without the toxicity of free cispla...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Kates, Max, Date, Abhijit, Yoshida, Takahiro, Afzal, Umara, Kanvinde, Pranjali, Babu, Taarika, Sopko, Nikolai A., Matsui, Hotaka, Hahn, Noah M., McConkey, David J., Baras, Alexander, Hanes, Justin, Ensign, Laura, Bivalacqua, Trinity J.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6487844/
https://ncbi.nlm.nih.gov/pubmed/28808039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1082
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars